GRAIL, Inc.(GRAL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,449 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
GRAL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for GRAIL, Inc. (GRAL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GRAL at 31.6/100 on a 32-signal composite quality model, placing it at rank #2,449 of 2,961 stocks — the bottom half of the AI-ranked universe. GRAL scores in the top quartile across revenue growth (86.1). Areas of concern include free cash flow (4.9) and profitability (5.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GRAIL, Inc. reports quarterly revenue of $44.7M, net income of $-110.2M, free cash flow of $-81.2M. Top institutional holders of GRAL by reported 13-F value include FARALLON CAPITAL MANAGEMENT, BAKER BROS. ADVISORS, BlackRock, based on the most recent SEC filings. GRAL trades on the Nasdaq exchange and files with the SEC under CIK 1699031. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRAL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GRAIL, Inc. directly from SEC EDGAR. GRAIL, Inc.'s 13F Pro composite quality score has ranged between 14 and 32 since 2025, currently 31.6 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$44.7M
Net Income
Q2 2026
$-110.2M
Free Cash Flow
Q2 2026
$-81.2M
ROIC
Q2 2026
-27.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+17.2% YoYNet Income
+79.9% YoYOperating Income
+74.3% YoYEPS (Diluted)
+82.5% YoYTotal Assets
-2.1% YoYOp. Cash Flow
+48.2% YoYFree Cash Flow
+48.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $147.2M +17.2% | $125.6M +34.9% | $93.1M +67.6% | $55.5M |
| Net Income | $-408.4M +79.9% | $-2.03B -38.3% | $-1.47B +72.9% | $-5.40B |
| Operating Income | $-562.2M +74.3% | $-2.19B -44.5% | $-1.52B +72.2% | $-5.44B |
| EPS (Diluted) | $-11.11 +82.5% | $-63.54 -34.6% | $-47.21 +72.9% | $-173.89 |
| Total Assets | $2.92B -2.1% | $2.98B -23.8% | $3.91B | — |
| Operating Cash Flow | $-299.0M +48.2% | $-577.2M +3.1% | $-595.8M -6.1% | $-561.3M |
| Free Cash Flow | $-299.9M +48.5% | $-582.4M +4.3% | $-608.7M -4.2% | $-584.2M |
Get alerted when GRAL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GRAIL, Inc. including:
Top Institutional Holders of GRAL
FARALLON CAPITAL MANAGEMENT LLC
$284.1M4,161,584 shBAKER BROS. ADVISORS LP
$275.0M4,028,614 shBlackRock, Inc.
$244.2M3,577,075 shSTATE STREET CORP
$162.9M2,385,514 shPRIMECAP MANAGEMENT CO/CA/
$148.8M2,180,106 shSessa Capital IM, L.P.
$139.1M2,037,518 shDeep Track Capital, LP
$125.3M1,834,944 shVANGUARD CAPITAL MANAGEMENT LLC
$112.0M1,641,117 shMORGAN STANLEY
$99.8M1,462,163 shArbiter Partners Capital Management LLC
$70.6M1,034,297 sh
| Fund | Value | Shares |
|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | $284.1M | 4,161,584 |
| BAKER BROS. ADVISORS LP | $275.0M | 4,028,614 |
| BlackRock, Inc. | $244.2M | 3,577,075 |
| STATE STREET CORP | $162.9M | 2,385,514 |
| PRIMECAP MANAGEMENT CO/CA/ | $148.8M | 2,180,106 |
| Sessa Capital IM, L.P. | $139.1M | 2,037,518 |
| Deep Track Capital, LP | $125.3M | 1,834,944 |
| VANGUARD CAPITAL MANAGEMENT LLC | $112.0M | 1,641,117 |
| MORGAN STANLEY | $99.8M | 1,462,163 |
| Arbiter Partners Capital Management LLC | $70.6M | 1,034,297 |
Companies Similar to GRAL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Beam Therapeutics Inc.
Twist Bioscience Corp
Adaptive Biotechnologies Corp
Butterfly Network, Inc.
RHYTHM PHARMACEUTICALS, INC.
Guardant Health, Inc.
Kura Oncology, Inc.
Prime Medicine, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put GRAL on your watchlist
Track score changes the day GRAIL, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GRAL a good stock to buy?
13F Pro's AI-powered analysis of GRAIL, Inc. (GRAL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GRAL are available on the GRAL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GRAL is classified as a mid company.
Which hedge funds own GRAL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GRAL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GRAIL, Inc.'s investment landscape.